Modality
ADC
MOA
KRASG12Ci
Target
CD20
Pathway
Ferroptosis
Narcolepsy
Development Pipeline
Preclinical
~Sep 2009
→ ~Dec 2010
Phase 1
~Mar 2011
→ ~Jun 2012
Phase 2
~Sep 2012
→ ~Dec 2013
Phase 3
~Mar 2014
→ ~Jun 2015
NDA/BLA
~Sep 2015
→ ~Dec 2016
Approved
Mar 2017
→ Jan 2026
ApprovedCurrent
NCT07432594
2,662 pts·Narcolepsy
2024-11→2026-01·Completed
NCT05533244
292 pts·Narcolepsy
2017-03→TBD·Completed
2,954 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-01-123mo agoPh3 Readout· Narcolepsy
2026-06-273mo awayAdCom· Narcolepsy
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2026-01-12 · 3mo ago
Narcolepsy
AdCom
2026-06-27 · 3mo away
Narcolepsy
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07432594 | Approved | Narcolepsy | Completed | 2662 | SRI-4 |
| NCT05533244 | Approved | Narcolepsy | Completed | 292 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Niralucimab | Ionis | Phase 1 | ALK |